Glucocorticoid-remediable aldosteronism (GRA) is
Introduction
Glucocorticoid-remediable aldosteronism (GRA)-also called dexamethasone-suppressible hyperaldosteronism-is a rarely recognised cause of secondary hypertension in children. 1 To date, there are only a few reports of GRA causing hypertension in children in the recent literature. 2, 3 GRA was the first monogenic form of arterial hypertension in which a responsible gene was identified 4 and it is now known to be an autosomal dominant inherited condition as a direct molecular genetic analysis is currently feasible. GRA is generally characterised by arterial hypertension, hyperaldosteronism, very low plasma renin activity and hypokalaemia, although hypokalaemia is not a consistent laboratory finding. Mancia and coworkers, 5 in a review on ambulatory blood pressure monitoring (ABPM) include primary hyperaldosteronism among a list of conditions poss- During the next 2 months of dexamethasone therapy all three antihypertensive drugs were discontinued and BP remained under control with restoration to a normal nocturnal BP fall (mean daytime BP 129/77 mm Hg, mean night-time BP 113/64, nocturnal BP fall 12/17%). A change of therapy from dexamethasone to spironolactone was necessary due to the side effects of corticosteroids after 3 months. Spironolactone alone (0.8-2 mg/kg/day) was able to control the BP sufficiently.
In conclusion, to our knowledge, this is the first reported case of abolished nocturnal BP fall in a patient with genetically proven GRA. This study indicates that GRA can cause severe hypertension even in children, associated with an abolished nocturnal BP fall. GRA thus should be excluded in all hypertensive patients with circadian BP rhythm disturbances.
ibly associated with the reduction or abolition of nocturnal BP fall. The disturbances of nocturnal BP fall are supposed to be associated with greater cardiovascular morbidity and mortality 6 although the true diagnostic and prognostic significance of the absence of a nocturnal BP fall remains controversial. To date there are no documented reports of disturbed circadian BP rhythm in patients with genetically proven GRA. Here we report on the case of a boy with GRA suffering from a severe hypertension associated with abolished nocturnal BP fall.
Case report
A routine paediatric check on a 13-year-old previously healthy boy revealed an elevated casual BP (140/95 mm Hg and the 95th percentile, according to the Report on the Second Task Force 7 was 129/81). He was reported normotensive on prior checks, did not complain about any symptoms and no abnormalities were found on physical examination. Further examinations in a paediatric cardiological out-patients department utilising electrocardiography and echocardiography showed signs of left ventricular hypertrophy (interventricular septum (IVS) 14 mm, ie, 182% of the norm, diastolic left ventricular posterior wall thickness (LVPWd) 12 mm, ie, 169% of the norm) but no signs of coarctation of the aorta. There were also no signs of renal disease as urinanalysis or serum creatinine and renal ultrasonography were normal.
Antihypertensive drug monotherapy with metipranolol was initiated but it was not effective in reducing elevated BP. Therefore a combination of metipranolol and hydrochlorothiazide was recommended but even on this medication the casual BP remained elevated (140-160/75-95 mm Hg).
Following 4 months of unsuccessful treatment for hypertension of unknown aetiology, the boy was referred for evaluation by our paediatric nephrology policlinic. Despite combined antihypertensive therapy elevated casual BP of 150/95 mm Hg was noted with no observed abnormality on the physical examination. Moreover, the family history was relevant as paternal hypertension was also detected in adolescent age. The origin of the father's hypertension was unknown and despite combination therapy (betaxolol and enalapril) his casual BP remained elevated (190/114 mm Hg).
ABPM (oscillometric device SpaceLabs 90207 (Spacelabs, Redmond, WA, USA) BP recorded every 20 min during the day and every 30 min overnight) without medication (5 days off medications) was then subsequently undertaken. The boy slept well through the night and tolerated well the whole ABPM procedure. ABPM revealed a significant daytime hypertension and a severe night-time hypertension with abolished nocturnal BP fall (mean daytime BP 155/108 mm Hg, mean night-time BP 156/104 mm Hg; 95th percentile according to Soergel et al 8 was 134/85 at daytime and 118/67 at nighttime; nocturnal BP fall 0/4%; Figure 1 ). This result suggested secondary hypertension and the boy was admitted to our paediatric department to elucidate the cause of the hypertension. The boy was not obese (50.7 kg, 170 cm) and did not complain about headache, epistaxis or other symptoms of hypertension. We began the treatment with a new oral combination therapy, consisting of nifedipine and atenolol, which tended to slowly decrease the elevated BP, but the control of hypertension remained unsatisfactory. We did not use angiotensin-converting enzyme inhibitors due to the indication of renovascular hypertension and therefore a potent vasodilator, minoxidil, was added. Blood pressure thereafter dropped to around 140/90 mm Hg which was nevertheless still slightly above the 95th percentile.
The first laboratory examinations showed normal urinanalysis, normal creatininaemia, normal abdomen sonography with no signs of tumour or renoparenchymal disease. The only pathological finding was hypokalaemia of 3.0 mmol/l. The results of plasma renin activity (PRA) and plasma aldosterone (samples taken after temporary withdrawal of antihypertensive drugs) were still not available at that time. Ultrasonography and CT focusing on adrenal glands showed no signs of adrenal tumour or hyperplasia. As we suspected renovascular hypertension, we performed renal angiography which showed no stenosis of the renal arteries or their branches. Thereafter, we instituted enalapril therapy instead of minoxidil because of hypertrichosis. Despite these efforts and triple antihypertensive therapy, there was still insufficient BP control. Further laboratory tests revealed elevated plasma aldosterone level and suppressed PRA (Table 1) . Additionally, ACTH concentration was also slightly elevated (107 ng/l, normal range 1-100 ng/l).
The findings of severe hypertension with abolished nocturnal BP fall, positive family history of early onset hypertension, hypokalaemia, suppressed PRA, elevated plasma aldosterone and absent adenoma or hyperplasia of the adrenal gland led us to the clinical diagnosis of GRA and therapy with Figure 2 ). For the genetic analysis the DNA was extracted from the blood of the boy and his father and mother. The newly developed PCR-based genetic test used is described in the next section. The chimaeric GRA-gene was detected in the DNA of the father and of the son ( Figure 3) . A Southern blot was not performed because of the matching biochemical and genetic data of all three family members. Three months after commencement of dexamethasone therapy, normal BP was reported (casual home BP 110-125/60-75 mm Hg) and the laboratory data showed normalisation of plasma aldosterone, PRA and kalaemia ( Table 1 ). The direct molecular genetic test was positive for the presence of the GRA-gene in the boy as well as in his father. This result confirmed our diagnosis of GRA which was at first based only on clinical and biochemical data.
In the next few months the boy became cushingoid (weight gain 15 kg) with marked suppression of cortisol secretion (serum level 9 nmol/l, normal range 150-500). Over the course of the next 3 months dexamethasone was carefully discontinued and spironolactone therapy initiated. One month after the switch of therapy (full initial dose of spironolactone was 2 mg/kg/day) the BP remained normal as well as the circadian BP rhythm (casual BP 125/75 mm Hg, mean daytime BP 123/73 mm Hg, mean night-time BP 112/61 mm Hg, nocturnal BP fall 9/16%) and the cortisol serum level normalised (185 nmol/l). The dose of spironolactone was reduced to 1 mg/kg/day after a slight gynecomastia occurred.
The patient is now taking spironolactone for 14 months only (present dose 0.8 mg/kg/day) with a normal home BP of 110-120/70-75 mm Hg and slight gynecomastia without influence on puberty (appropriate sexual maturation, normal testosterone levels). Left ventricular hypertrophy improved considerably after 14 months of treatment (LVPWd decreased to 133% of the norm).
Recently we have diagnosed GRA in another 15-year-old boy who also presented with severe hypertension (casual BP 140/100 mm Hg) and left ventricular hypertrophy (LVPWd 135% of the norm). The diagnosis was also proven genetically. He showed similar laboratory values as the first boy (Table 1) but ABPM revealed fully conserved nocturnal BP fall (10/22%, daytime BP 151/91 mm Hg, night-time BP 137/71 mm Hg). He was not treated by dexamethasone and we have treated him from the beginning with spironolactone and he is now on spironolactone and amiloride therapy and his casual BP is 135/85 mm Hg.
Genetic analysis of the chimaeric GRAgene
The molecular genetic test can be done with a single PCR according to our previously published procedure. 9 In brief, a set of three primers were used in this reaction. Primer 210 (5′-AAACACAGGCCCT GACCCGTATCCC-3′, antisense) has a concentration of 4 nmol/l in the reaction mix. It is bound to a specific sequence on intron 2 of the 11␤-hydroxylase gene. The other two primers are 200 nM in concentration. Primer 212A (5′-GAGCGTCATCAGCAA CGGAAACGCT-3′, antisense) binds to exon 6 of the aldosterone synthase gene, and primer 209 (5′-CCCATGACGTGATCCCTCTCGAAGG-3′, sense) binds to a sequence on the 11␤-hydroxylase promoter. A 50 l reaction mixture contains 200 M of each nucleotide, 200-400 ng genomic DNA from the patient, 1.5 mM MgCl 2 , 50 mM KCl, 10 mM Tris (pH 9), 0.01% gelatine, 0.1% Triton X-100 and 2.5 units Taq polymerase (AmpliTaq * , Perkin-Elmer). The cycling programme was 35 × 94°C for 1 min, 64°C for 2 min and 72°C for 5 min.
In a case of an existing chimaeric GRA gene in the patient's genome, primer 209 and 212A produce a specific 4.4 kbp-product. The primer 210 is added to the reaction as a control. This primer amplifies together with primer 209 a 2.7-kbp long fragment of the 11␤-hydroxylase. In GRA-negative patients only this fragment is visible on the agarose gel suggesting that PCR conditions and possible degraded or unamplifyable DNA were not the reasons for the negative result. Figure 3 shows the agarose gel with the PCR fragments obtained from the family examined. Two independent PCR reactions were made per family member. It can be clearly demonstrated that the patient has the chimeric gene (lanes 3). The mother is unaffected (lanes 2), but the father of the patient also possesses the chimera resulting in hypertension (lanes 1).
Discussion
Arterial hypertension in children is caused mainly by renoparenchymal or renovascular disorders. Endocrinological disorders causing hypertension in children are rarely recognised. 10 Pheochromocytoma and disturbances of steroidogenesis (11␤-and 17␣-hydroxylase deficiency) were regarded as the most common forms of endocrine hypertension in one published review. 10 Primary aldosteronism is a rarely diagnosed endocrine cause of hypertension in children. It is presented by three major subtypes: aldosterone-producing adenoma, bilateral hyperplasia and GRA. In contrast to adenoma or hyperplasia GRA usually shows no anatomical abnormality of the adrenal glands on CT scans.
The diagnosis of GRA in our patient was based on clinical, laboratory and molecular genetic data. Our patient showed a positive hypertensive family history (father suffered from hypertension from adolescence). Clinical examination showed a severe hypertension with an abolished nocturnal BP fall which is typical for secondary forms of hypertension. Primary hyperaldosteronism and its form, GRA, is associated with diseases which are noted for a reduction or even abolition of nocturnal BP fall. 5 The presence of hypertension and its severity is very variable in GRA ranging from normal BP in 44 -67% of patients with GRA 11 to severe hypertension. 12 However, to date, there are no published data on abolished nocturnal BP fall in patients with genetically proven GRA. In a recent study by Rabbia et al 13 all four adult patients with GRA showed normal nocturnal BP fall. Thus, our study is the first to demonstrate a disturbed circadian BP rhythm due to an abolished nocturnal BP fall in a patient with GRA. Our case report is a further contribution to the diagnostic significance of BP rhythm disturbances in childhood patients with secondary hypertension. The absence of a nocturnal BP fall is believed to also have prognostic significance causing greater cardiovascular morbidity. 6 This hypothesis is also supported by our patient who showed a severe target organ damage (severe left ventricular hypertrophy). The abolished nocturnal BP was neither caused by sleep disturbances, as the boy slept well, nor by medications as he was 5 days off medication with quite short-term action (metipranolol and hydrochlorothiazid). He also did not take any other drugs.
Laboratory evaluations in our patient showed all typical signs of GRA-hypokalaemia, low PRA and high plasma aldosterone. It is not proposed that the extremely low PRA could be a possible effect of medication as the short acting beta-blocker metipranolol which would tend to lower the PRA was ceased 6 days before blood samples were collected. The level of ACTH was slightly elevated although in GRA the levels of ACTH are normal. The reason for this discrepancy is not known, the slight elevation could possibly be caused by stress in the hospital or by an intra-assay variability.
The diagnosis was further confirmed by the successful treatment of hypertension by dexamethasone, and subsequent normalisation of potassium, PRA and plasma aldosterone levels and finally by the presence of a chimaeric gene indicative for GRA. Molecular analysis which has 100% specificity for GRA, also confirmed the diagnosis in the father of our patient.
In a recent paper on GRA in a child 3 the laboratory data showed only low PRA with normal plasma aldosterone and serum potassium levels. Potassium and aldosterone levels are frequently normal in GRA. 12 In this case report 3 the child has been treated from the beginning of the disease by the alternative drug for GRA-the aldosterone antagonist, spironolactone. However, there are no studies on the efficacy and safety of the treatment for GRA which currently consists of the use of one of the following drugs: dexamethasone, prednisone, spironolactone or amiloride.
In this report glucocorticoid therapy was successful enough to treat hypertension with a complete restoration of the circadian BP rhythm together with normalisation of serum potassium level, PRA and aldosterone levels due to the suppression of ACTH, with diminished stimulation of ectopic aldosterone synthase in the adrenocortical zona fasciculata. ACTH secretion was probably suppressed owing to the marked reduction in cortisol level in this patient.
Because of cushingoid features at follow-up we had to change the therapy to an alternative drug, spironolactone. The dexamethasone dose seems to be too high and, therefore, we reduced the initial dose of 0.5 mg b.i.d. gradually to 0.125 mg b.i.d. Spironolactone alone was as effective as dexamethasone in the control of the BP level as well as the BP rhythm but also had its adverse effects (gynecomastia). There are no dose recommendations for children with GRA. We would suggest from our experience to start the treatment with a lower dose of either spironolactone or dexamethasone and to closely monitor the child during the treatment in order to detect side effects as early as possible. Spironolactone monotherapy seems, at least in the short term (14 months in our case, 2 years in the case published by Yui et al 3 ) , to be as effective as glucocorticoids. We have recently diagnosed GRA in another boy who also presented with severe hypertension. He had comparable laboratory findings to the first boy regarding hypokalaemia, plasma aldosterone levels and plasma renin activity, but his nocturnal BP fall was completely normal. We could not find any relationship between BP levels and biochemical features of GRA. This finding is in agreement with the recent studies 14, 15 showing no correlation between BP levels and biochemical values in patients with primary hyperaldosteronism caused by adenoma, bilateral hyperplasia or idiopathic hyperaldosteronism. Up to now, there are no similar data in patients with GRA. The reason for this clinical heterogeneity and for the lack of correlation between the clinical and laboratory data is unclear. In a recent study Uzu et al 16 found attenuated nocturnal BP fall in patients with unilateral adrenal adenoma during a normal sodium diet but not during a low sodium diet. He speculated that when sodium intake is relatively high, the defect in excretory capability in patients with sodium-sensitive types of hypertension becomes evident. This phenomenon will lead to a BP increase at night in order to compensate for diminished natriuresis during the daytime and increased pressure natriuresis during the night. When sodium intake is low, the defect remains latent, allowing a lower BP at night. We could speculate that the level of the sodium retention was higher in the first boy and that it could produce the BP increase at night according to Uzu's hypothesis. The true pathogenesis of the attenuated nocturnal BP fall in some patients with different forms of primary hyperaldosteronism remains undetermined and requires further study.
Milder end-organ damage in the second boy with normal nocturnal BP fall (considerably milder left ventricular hypertrophy in the second boy in comparison to the first boy) supports the prognostic significance of the nocturnal BP fall regarding target organ damage. 6 Furthermore the finding of normal nocturnal BP fall in the second boy underlines the exceptionality of the disturbed circadian BP pattern in our first patient.
In conclusion, to our knowledge, this is the first reported case of abolished nocturnal BP fall documented with ABPM in a patient with genetically proven GRA. This study highlighted that GRA can cause severe hypertension with abolished nocturnal BP fall even in children and, albeit a relatively easy diagnosis and treatment, it should be excluded in all severely hypertensive patients with target organ damage and no signs of renal cause of hypertension.
